Novo Nordisk Takes On Sanofi Over Insulin Pens
Denmark-based drug maker Novo Nordisk A/S has filed a suit against Sanofi-Aventis and its U.S. affiliate for allegedly infringing an injection device patent through the French pharmaceutical company's yet-to-be-launched insulin pen...To view the full article, register now.
Already a subscriber? Click here to view full article